SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics" or the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscr ...

Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Announced a $350 Million Private Placement Equity Financing "As we reflect on our achievements in 2023, this was a truly significant year for Crinetics, laying the foundation for our next phase of growth," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Our lead investigational compound, paltusotine, continues to demonstrate highly promising resul ...

公司薪酬奖励 - Crinetics Pharmaceuticals, Inc.宣布董事会薪酬委员会授予了九名新的非执行员工73,000股普通股的非合格股票期权奖励[1] - 期权的行权价格为每股39.46美元，与2024年2月9日在纳斯达克全球精选市场上Crinetics的普通股收盘价相等[3] 公司背景介绍 - Crinetics Pharmaceuticals是一家临床阶段的制药公司，专注于发现、开发和商业化用于内分泌疾病和内分泌相关肿瘤的新型治疗药物[5]

10. EQUITY INCENTIVE PLANS The Company adopted the 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan") in December 2021. The Company initially reserved 1,500,000 shares of the Company's common stock for issuance pursuant to awards granted under the 2021 Inducement Plan. The terms of the 2021 Inducement Plan are substantially similar to the terms of the Company's 2018 Incentive Award Plan with the exception that awards may only be made to an employee who has not previously been an em ...

公司产品及研发进展 - 公司是一家专注于发现、开发和商业化新型内分泌疾病和内分泌相关肿瘤治疗药物的临床阶段制药公司[104] - 公司的主要产品候选包括paltusotine和CRN04894，分别用于治疗肢端肥大症和神经内分泌肿瘤，以及ACTH过多引起的疾病[105] - paltusotine在临床试验中表现出良好的耐受性，并在维持IGF-1水平方面取得了积极成果[107] - 公司正在进行paltusotine在肢端肥大症和神经内分泌肿瘤患者中的安全性和药代动力学评估的第二阶段试验[109] - 公司与Sanwa Kagaku Kenkyusho Co., Ltd.签订了独家许可协议，授予Sanwa在日本开发和商业化paltusotine的专有权[110] - CRN04894是公司的一种口服非肽类产品候选药物，旨在拮抗ACTH受体，用于治疗由ACTH过多引起的疾病，包括库欣氏病和CAH[111] - 公司已与美国国立卫生研究院的国家糖尿病和消化肾脏疾病研究所签订了一项临床试验协议，合作进行CRN04894在ACTH依赖性库欣氏综合征患者中的多剂量探索性试验[114] - 公司已向美国食品和药物管理局提交了CRN04894在CAH研究中的新药申请，并计划在2024年提交新药申请[116] - CRN04777是公司的一种口服非肽类生长抑素受体5型（SST5）激动剂，旨在治疗先天性高胰岛素血症，已在健康志愿者中展示了潜在的药理学概念[117] - CRN04777的美国临床研究计划被FDA暂停，因为额外的毒理学研究发现了影响其预期治疗边际的结果[118] - 开发钙化素受体拮抗剂用于治疗原发性甲状旁腺功能亢进症和恶性高钙血症等疾病[119] - 开发非肽类药物用于治疗原发性常染色体显性多囊肾病[120] - 成立Radionetics Oncology, Inc.，旨在开发新型放射性药物用于治疗广泛的肿瘤[121] - 持续评估新的治疗选择，计划扩大药物发现工作，包括代谢性疾病和Graves'病等[122] - 成立Crinetics Australia Pty Ltd，用于进行产品和开发候选者的临床和临床活动[123] 财务状况及资金情况 - 自成立以来，公司主要通过研究和发展补助、优先股私募和普通股销售资助运营[125] - 预计支出和运营亏损将大幅增加，特别是在进行临床试验、研究和发展活动以及雇佣额外人员方面[126] - 预计在未来一段时间内不会从产品销售中产生收入，可能通过股权发行、债务融资或其他资本来源融资现金需求[127] - 截至2023年6月30日，公司拥有现金、现金等价物和投资证券共计2.645亿美元，累计赤字为5.361亿美元[168] - 2023年6月30日，经营活动中的净现金流出为8.6453亿美元，投资活动中的净现金流入为8.0191亿美元，融资活动中的净现金流入为1.3142亿美元[169] - 2023年6月30日，公司完成了562.5563万股普通股的跟投后续发行，每股价格为22.22美元，净收益约为1.172亿美元[177] - 2023年6月30日，公司通过ATM Offering发行了52.2807万股普通股，净收益约为1.13百万美元[178]

FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 2 Condensed Consolidated Balance Sheets See the accompanying notes to these unaudited condensed consolidated financial statements. See the accompanying notes to these unaudited condensed consolidated financial statements. (In thousands) (Unaudited) 1. ORGANIZATION AND BASIS OF PRESENTATION Unaudited Interim Financial Information ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

产品和技术研发 - 公司正在开发针对内分泌紊乱和内分泌相关肿瘤的口服小分子药物[1] - 发现实验室已成功开发出有效的药物候选物[8] - CRN04894和CRN04777是用于治疗Cushing's Disease和Hyperinsulinism的首创口服小分子药物[24] - 公司的GPCR发现和开发引擎持续推进新资产，针对高发性内分泌紊乱疾病[38] 市场扩张和并购 - 公司致力于建立全球领先的内分泌公司，拥有多个产品的全球批准[5] - 目前美国市场上的内分泌治疗市场规模为7亿美元，总可寻址市场规模为32亿美元[16] - 公司的产品在Acromegaly和Carcinoid Syndrome患者中有潜在市场需求[16][27][34] 未来展望 - Paltusotine的开发计划旨在支持潜在的广泛应用，包括在未治疗的Acromegaly患者中评估其安全性和有效性[22] - CRN04777针对先天性和综合性高胰岛素血症市场机会巨大，美国患者数量估计在1700-2200之间[34] - 公司在PATHFNDR-1和PATHFNDR-2研究中持续评估Paltusotine的疗效和安全性[42][43] 其他有价值的信息 - 目前可用的SRLs治疗Acromegaly患者的效果不佳，有33-55%的患者在注射SRLs后报告症状恶化[17] - 先天性高胰岛素血症(CHI)是一种由胰岛素分泌过多引起的疾病，可导致严重低血糖[33] - 公司的口服药物CRN04777针对儿童提供了一种友好的治疗方案[36]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select Market FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select Market FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...